Table of Contents

company-logo

Burning Rock Biotech Limited primarily develops and provides cancer therapy selection tests in the People's Republic of China. It operates in three segments: Central Laboratory Business, In-Hospital Business, and Pharma Research and Development Services. The company primarily offers next-generation sequencing-based cancer therapy selection and prognosis prediction tests applicable to a range of cancer types, including lung cancer, gastrointestinal cancer, prostate cancer, breast cancer, lymphomas, thyroid cancer, colorectal cancer, ovarian cancer, pancreatic cancer, and bladder cancer using tissue and liquid biopsy samples. Its principal products include OncoCompass IO, a corresponding test for liquid biopsy samples; OncoScreen IO, a pan-cancer test for tissue samples; OncoCompass Target, a ctDNA liquid biopsy-based test for NSCLC; ColonCore for assessing microsatellite loci related to MSI status and detecting mutations in genes associated with gastrointestinal cancers; and OncoScreen ParpMatch and OncoCompass ParpMatch to target critical genes associated with homologous recombination deficiency. In addition, the company has development and commercialization agreement with Myriad Genetics, Inc. to in-license Myriad myChoice tumor testing in China; and licensing agreement with Oncocyte Corporation to in-license DetermaRx, a risk stratification test for early stage lung cancer patients in China. It has collaborations on clinical trials and research studies with AstraZeneca, Bayer, Johnson & Johnson, CStone, BeiGene, Abbisko Therapeutics, and IMPACT Therapeutics and Merck KGaA. The company was incorporated in 2014 and is headquartered in Guangzhou, China.

Burning Rock Biotech Dividend Announcement

• Burning Rock Biotech does not currently offer dividends, we're keeping a close eye on its growth potential and financial developments.
• Stay tuned for updates on Burning Rock Biotech dividend policy and future announcements. In the meantime, explore other dividend-yielding opportunities on our website.

Burning Rock Biotech Dividend History

Burning Rock Biotech Dividend Yield

Burning Rock Biotech current trailing twelve-month (TTM) dividend yield is -%. Interested in purchasing Burning Rock Biotech stock? Use our calculator to estimate your expected dividend yield:

Burning Rock Biotech Financial Ratios

P/E ratio-0.49
PEG ratio0.00
P/B ratio0.41
ROE-74.92%
Payout ratio0.00%
Current ratio3.11
Quick ratio2.85
Cash Ratio2.05

Burning Rock Biotech Dividend FAQ

Does Burning Rock Biotech stock pay dividends?
Burning Rock Biotech does not currently pay dividends to its shareholders.
Has Burning Rock Biotech ever paid a dividend?
No, Burning Rock Biotech has no a history of paying dividends to its shareholders. Burning Rock Biotech is not known for its dividend payments.
Why doesn't Burning Rock Biotech pay dividends?
There are several potential reasons why Burning Rock Biotech would choose not to pay dividends to their shareholders:

1. Growth opportunities: Companies, especially in fast-growing industries like technology, reinvest earnings into expansion, R&D, or acquisitions to fuel future growth and increase company value.

2. Tax implications: Not paying dividends can reduce the tax burden on shareholders, who may prefer to defer taxes until selling shares and realizing capital gains.

3. Investor preferences: Some investors prefer companies to reinvest profits for higher long-term returns, particularly those seeking capital appreciation over income.

4. Capital allocation priorities: Companies may allocate cash to pay down debt, fund share buybacks, or invest in projects with higher returns than dividends.

5. Market expectations: In certain sectors, like technology, reinvesting profits for growth and innovation is often prioritized over distributing dividends to shareholders.
Will Burning Rock Biotech ever pay a dividend?
The decision for a company to pay dividends depends on various factors including its financial performance, growth prospects, capital allocation priorities, and shareholder preferences. While Burning Rock Biotech has not paid dividends historically and has instead focused on reinvesting its earnings for growth, it's ultimately up to the company's management and board of directors to decide whether to initiate a dividend policy in the future.
Is Burning Rock Biotech a dividend aristocrat?
Burning Rock Biotech is not considered a Dividend Aristocrat. The term "Dividend Aristocrat" is typically used to describe a company in the S&P 500 index that has increased its dividend payouts for at least 25 consecutive years.
Is Burning Rock Biotech a dividend king?
Burning Rock Biotech is not classified as a "Dividend King". A Dividend King is a company that has managed to increase its dividend payouts for 50 consecutive years or more, which is an even more selective group than the Dividend Aristocrats.
Is Burning Rock Biotech a dividend stock?
No, Burning Rock Biotech is not considered a dividend stock. A dividend stock is a stock of a company that regularly pays out dividends to its shareholders.
How to buy Burning Rock Biotech stocks?
To buy Burning Rock Biotech you need a brokerage account. Open an account with a reputable brokerage firm that offers access to the stock market. Consider factors such as fees and account minimums.

Place an order: Use the brokerage's trading platform to place an order to buy Burning Rock Biotech stock.

Remember that buying stocks involves risk, and it's important to carefully consider your investment goals, risk tolerance, and conduct thorough research before making any investment decisions.